Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic range
暂无分享,去创建一个
C. Gonde | J. Tredger | M. Rela | N. Heaton | A. Dhawan | N. Brown | J. Adams | Jemimah E. Adams | N. W. Brown
[1] H. Adami,et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden , 2003, British Journal of Cancer.
[2] M. H. Ensom,et al. Mycophenolate Mofetil for Solid Organ Transplantation: Does the Evidence Support the Need for Clinical Pharmacokinetic Monitoring? , 2003, Therapeutic drug monitoring.
[3] C. Gonde,et al. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[4] W. Nahas,et al. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation , 2003, Pediatric Nephrology.
[5] J. Tredger,et al. Mycophenolic Acid and Mycophenolic Acid Glucuronide Pharmacokinetics in Pediatric Liver Transplant Recipients: Effect of Cyclosporine and Tacrolimus Comedication , 2002, Therapeutic drug monitoring.
[6] K. Eckardt,et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. , 2002, Journal of the American Society of Nephrology : JASN.
[7] D. Holt. Monitoring mycophenolic acid , 2002, Annals of clinical biochemistry.
[8] L. Weber,et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. , 2002, Journal of the American Society of Nephrology : JASN.
[9] L. Weber,et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. , 2002, Clinical chemistry.
[10] L. Shaw,et al. Monitoring of Mycophenolic Acid in Clinical Transplantation , 2002, Therapeutic drug monitoring.
[11] L. Shaw,et al. Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable Discussion , 2001, Therapeutic drug monitoring.
[12] J. Fung,et al. Pharmacokinetics of Mycophenolic Acid after Mycophenolate Mofetil Administration in Liver Transplant Patients Treated with Tacrolimus , 2001 .
[13] L. Shaw,et al. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. , 2001, Clinical biochemistry.
[14] J. Squifflet,et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. , 2001, Clinical chemistry.
[15] L. Shaw,et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[16] C. Cantarell,et al. Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy. , 2000, Pharmacology & toxicology.
[17] N. Smedira,et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. , 2000, Transplantation.
[18] V. Armstrong,et al. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. , 2000, Clinical chemistry.
[19] L. Weber,et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. , 2000, Therapeutic drug monitoring.
[20] L. Shaw,et al. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. , 2000, Therapeutic drug monitoring.
[21] G. Filler,et al. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression , 2000, Pediatric Nephrology.
[22] L. Weber,et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. , 1999, Therapeutic drug monitoring.
[23] D. Holt,et al. Therapeutic drug monitoring of immunosuppressant drugs. , 1999, British journal of clinical pharmacology.
[24] W. Weimar,et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] A. Tsaroucha,et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. , 1999, Therapeutic drug monitoring.
[26] H. Reichenspurner,et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[27] L. Weber,et al. Pharmacokinetics of mycophenolic acid (MPA) and free MPA in paediatric renal transplant recipients--a multicentre study. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[28] A. Nicholls. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. , 1998, Clinical biochemistry.
[29] W. Weimar,et al. Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients. , 1998, Transplantation proceedings.
[30] A. Nicholls,et al. Clinical Pharmacokinetics of Mycophenolate Mofetil , 1998, Clinical pharmacokinetics.
[31] A. Trull. Therapeutic Monitoring of Tacrolimus , 1998, Annals of clinical biochemistry.
[32] J. Squifflet,et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. , 1998, Transplantation.
[33] Mark A. Murcko,et al. Structure and Mechanism of Inosine Monophosphate Dehydrogenase in Complex with the Immunosuppressant Mycophenolic Acid , 1996, Cell.
[34] B. Kahan. The Evolution of Therapeutic Immunosuppression and the Potential Impact of Drug Concentration Monitoring , 1995, Therapeutic drug monitoring.